The treatment group had fewer angina attacks, shorter duration, lower symptom scores, and a higher effective rate than the control group (P < .05). Serum ET-1 and hs-CRP levels were lower, and NO was higher (P < .05). Adverse reactions were similar (P > .05). This evidence concerns the gene EDN1 and angina pectoris.